Jeannette Lee
Concepts (469)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 22 | 2023 | 389 | 3.060 |
Why?
| | Anus Neoplasms | 10 | 2023 | 25 | 2.100 |
Why?
| | Stroke | 8 | 2024 | 512 | 1.910 |
Why?
| | Acquired Immunodeficiency Syndrome | 11 | 2022 | 54 | 1.570 |
Why?
| | Prostatic Hyperplasia | 10 | 2015 | 37 | 1.430 |
Why?
| | Brain | 10 | 2024 | 1323 | 1.390 |
Why?
| | Parkinson Disease | 2 | 2023 | 155 | 1.240 |
Why?
| | Randomized Controlled Trials as Topic | 8 | 2024 | 595 | 1.200 |
Why?
| | Chlamydia Infections | 8 | 2017 | 76 | 1.190 |
Why?
| | Papillomavirus Infections | 6 | 2022 | 173 | 1.140 |
Why?
| | Mesenchymal Stem Cell Transplantation | 2 | 2024 | 19 | 1.070 |
Why?
| | Sarcoma, Kaposi | 12 | 2022 | 76 | 1.040 |
Why?
| | Chlamydia trachomatis | 6 | 2017 | 29 | 1.000 |
Why?
| | Lymphoma, AIDS-Related | 10 | 2020 | 16 | 0.970 |
Why?
| | Brain Ischemia | 2 | 2023 | 161 | 0.890 |
Why?
| | Plant Extracts | 5 | 2013 | 194 | 0.880 |
Why?
| | Humans | 103 | 2025 | 52483 | 0.850 |
Why?
| | Serenoa | 5 | 2013 | 7 | 0.850 |
Why?
| | Phytotherapy | 3 | 2012 | 45 | 0.780 |
Why?
| | Rural Population | 4 | 2023 | 577 | 0.780 |
Why?
| | Umbilical Cord | 2 | 2020 | 36 | 0.770 |
Why?
| | Lymphoma, Non-Hodgkin | 6 | 2021 | 58 | 0.710 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 12 | 2021 | 1031 | 0.700 |
Why?
| | Middle Aged | 50 | 2021 | 13028 | 0.690 |
Why?
| | Research Design | 5 | 2022 | 359 | 0.680 |
Why?
| | Neonatal Abstinence Syndrome | 3 | 2024 | 27 | 0.640 |
Why?
| | Fetal Blood | 2 | 2019 | 80 | 0.640 |
Why?
| | Adult | 50 | 2022 | 14161 | 0.630 |
Why?
| | Male | 59 | 2024 | 26761 | 0.630 |
Why?
| | Inflammation | 3 | 2021 | 641 | 0.610 |
Why?
| | Patient Participation | 1 | 2018 | 69 | 0.580 |
Why?
| | Rats | 9 | 2024 | 3220 | 0.580 |
Why?
| | Vaginosis, Bacterial | 2 | 2015 | 8 | 0.540 |
Why?
| | Decision Making | 1 | 2018 | 282 | 0.510 |
Why?
| | Mammography | 1 | 2016 | 99 | 0.500 |
Why?
| | Antineoplastic Agents | 10 | 2023 | 1222 | 0.500 |
Why?
| | Neoplasms | 3 | 2023 | 1325 | 0.500 |
Why?
| | Stem Cells | 3 | 2025 | 177 | 0.500 |
Why?
| | Female | 47 | 2024 | 28171 | 0.480 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 6 | 2015 | 46 | 0.470 |
Why?
| | Aged | 28 | 2020 | 10121 | 0.460 |
Why?
| | Infarction, Middle Cerebral Artery | 3 | 2024 | 40 | 0.460 |
Why?
| | Population Density | 1 | 2014 | 16 | 0.460 |
Why?
| | Pelvic Inflammatory Disease | 2 | 2018 | 8 | 0.460 |
Why?
| | AIDS-Related Opportunistic Infections | 5 | 2016 | 38 | 0.460 |
Why?
| | Stem Cell Transplantation | 4 | 2025 | 185 | 0.450 |
Why?
| | Carcinoma in Situ | 3 | 2013 | 72 | 0.440 |
Why?
| | Cytokines | 5 | 2023 | 623 | 0.430 |
Why?
| | Animals | 14 | 2025 | 13505 | 0.420 |
Why?
| | Uterine Cervicitis | 1 | 2013 | 3 | 0.420 |
Why?
| | Anti-Bacterial Agents | 5 | 2020 | 807 | 0.420 |
Why?
| | Hydrocephalus, Normal Pressure | 1 | 2012 | 1 | 0.410 |
Why?
| | Urethritis | 2 | 2012 | 5 | 0.410 |
Why?
| | Finasteride | 4 | 2015 | 4 | 0.400 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 106 | 0.390 |
Why?
| | Research Subjects | 1 | 2013 | 52 | 0.390 |
Why?
| | Guideline Adherence | 1 | 2013 | 138 | 0.390 |
Why?
| | Breast Neoplasms | 3 | 2017 | 1212 | 0.380 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2012 | 60 | 0.380 |
Why?
| | Rats, Sprague-Dawley | 5 | 2024 | 1563 | 0.380 |
Why?
| | Patient Dropouts | 1 | 2012 | 51 | 0.370 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 170 | 0.370 |
Why?
| | Urologic Diseases | 1 | 2011 | 9 | 0.360 |
Why?
| | Homosexuality, Male | 4 | 2022 | 52 | 0.360 |
Why?
| | HIV-1 | 6 | 2020 | 59 | 0.360 |
Why?
| | Analgesics, Opioid | 4 | 2024 | 590 | 0.350 |
Why?
| | Lung Neoplasms | 2 | 2013 | 636 | 0.340 |
Why?
| | Disease Models, Animal | 5 | 2024 | 1478 | 0.340 |
Why?
| | Young Adult | 17 | 2019 | 4329 | 0.340 |
Why?
| | Papillomaviridae | 3 | 2019 | 105 | 0.330 |
Why?
| | United States | 10 | 2023 | 5192 | 0.330 |
Why?
| | Patient Selection | 1 | 2011 | 259 | 0.320 |
Why?
| | Quality of Life | 6 | 2024 | 879 | 0.320 |
Why?
| | Lymphedema | 2 | 2022 | 48 | 0.320 |
Why?
| | HIV Seropositivity | 3 | 2021 | 28 | 0.310 |
Why?
| | Lower Urinary Tract Symptoms | 3 | 2013 | 6 | 0.310 |
Why?
| | Intestinal Mucosa | 2 | 2021 | 224 | 0.310 |
Why?
| | Asthma | 2 | 2024 | 316 | 0.310 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2017 | 505 | 0.300 |
Why?
| | Gonorrhea | 2 | 2020 | 9 | 0.290 |
Why?
| | Azithromycin | 4 | 2020 | 26 | 0.290 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2022 | 299 | 0.290 |
Why?
| | Anal Canal | 4 | 2023 | 27 | 0.270 |
Why?
| | Th1 Cells | 2 | 2017 | 55 | 0.270 |
Why?
| | Risk Factors | 8 | 2022 | 3889 | 0.270 |
Why?
| | Prospective Studies | 12 | 2022 | 2481 | 0.270 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2017 | 182 | 0.260 |
Why?
| | Mycoplasma genitalium | 2 | 2018 | 2 | 0.250 |
Why?
| | Doxazosin | 3 | 2015 | 3 | 0.250 |
Why?
| | Mycoplasma Infections | 2 | 2018 | 7 | 0.250 |
Why?
| | Prevalence | 7 | 2021 | 1006 | 0.250 |
Why?
| | Treatment Outcome | 16 | 2020 | 5422 | 0.250 |
Why?
| | Cyclophosphamide | 9 | 2021 | 171 | 0.240 |
Why?
| | Doxycycline | 3 | 2015 | 33 | 0.240 |
Why?
| | Cancer Vaccines | 1 | 2006 | 78 | 0.240 |
Why?
| | Anti-Infective Agents | 2 | 2020 | 107 | 0.240 |
Why?
| | Vincristine | 8 | 2021 | 88 | 0.240 |
Why?
| | Adolescent | 13 | 2022 | 6739 | 0.230 |
Why?
| | Multicenter Studies as Topic | 4 | 2024 | 105 | 0.230 |
Why?
| | Circadian Rhythm | 1 | 2025 | 91 | 0.230 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2018 | 603 | 0.230 |
Why?
| | Air Filters | 1 | 2024 | 1 | 0.220 |
Why?
| | Double-Blind Method | 4 | 2013 | 713 | 0.220 |
Why?
| | CD4 Lymphocyte Count | 7 | 2020 | 33 | 0.220 |
Why?
| | Bronchiolitis | 1 | 2024 | 28 | 0.220 |
Why?
| | Air Pollution, Indoor | 1 | 2024 | 27 | 0.220 |
Why?
| | 5-alpha Reductase Inhibitors | 2 | 2015 | 3 | 0.220 |
Why?
| | Hyperbaric Oxygenation | 1 | 2023 | 15 | 0.210 |
Why?
| | Cell Differentiation | 3 | 2025 | 665 | 0.210 |
Why?
| | Substantia Nigra | 1 | 2023 | 14 | 0.210 |
Why?
| | alpha-Synuclein | 1 | 2023 | 9 | 0.210 |
Why?
| | Neoplasm Staging | 5 | 2022 | 772 | 0.210 |
Why?
| | Doxorubicin | 8 | 2021 | 241 | 0.210 |
Why?
| | Transplantation Conditioning | 2 | 2018 | 93 | 0.210 |
Why?
| | Cisplatin | 3 | 2022 | 285 | 0.210 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2017 | 399 | 0.210 |
Why?
| | Informatics | 1 | 2023 | 8 | 0.210 |
Why?
| | Prednisone | 7 | 2021 | 102 | 0.200 |
Why?
| | Herpesvirus 8, Human | 5 | 2020 | 98 | 0.200 |
Why?
| | Astrocytes | 1 | 2024 | 137 | 0.200 |
Why?
| | Follow-Up Studies | 8 | 2019 | 2279 | 0.200 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 1678 | 0.200 |
Why?
| | Brachytherapy | 1 | 2022 | 48 | 0.200 |
Why?
| | Neuroprotective Agents | 2 | 2020 | 101 | 0.200 |
Why?
| | Watchful Waiting | 1 | 2022 | 28 | 0.200 |
Why?
| | Oxidative Phosphorylation | 1 | 2022 | 46 | 0.190 |
Why?
| | Medical Records | 1 | 2022 | 87 | 0.190 |
Why?
| | Absorptiometry, Photon | 1 | 2003 | 162 | 0.190 |
Why?
| | Feasibility Studies | 2 | 2021 | 406 | 0.190 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 168 | 0.190 |
Why?
| | Vitamin D Deficiency | 1 | 2022 | 46 | 0.190 |
Why?
| | Brain Injuries | 1 | 2023 | 159 | 0.190 |
Why?
| | Viral Load | 6 | 2020 | 82 | 0.190 |
Why?
| | Vaccines | 1 | 2022 | 51 | 0.190 |
Why?
| | Genome-Wide Association Study | 3 | 2018 | 186 | 0.190 |
Why?
| | Precancerous Conditions | 1 | 2022 | 85 | 0.190 |
Why?
| | Child | 7 | 2024 | 7248 | 0.190 |
Why?
| | Case-Control Studies | 3 | 2014 | 1201 | 0.190 |
Why?
| | Lymphocyte Activation | 3 | 2017 | 172 | 0.190 |
Why?
| | Mouth Diseases | 1 | 2021 | 5 | 0.190 |
Why?
| | Clinical Trials as Topic | 5 | 2020 | 467 | 0.180 |
Why?
| | Vaccination | 3 | 2022 | 298 | 0.180 |
Why?
| | Thymus Gland | 1 | 2021 | 41 | 0.180 |
Why?
| | Mass Screening | 2 | 2015 | 357 | 0.180 |
Why?
| | Pluripotent Stem Cells | 1 | 2021 | 7 | 0.180 |
Why?
| | Progestins | 1 | 2020 | 11 | 0.180 |
Why?
| | Primary Health Care | 2 | 2022 | 376 | 0.180 |
Why?
| | Physical Conditioning, Animal | 1 | 2021 | 59 | 0.180 |
Why?
| | T-Lymphocyte Subsets | 2 | 2017 | 41 | 0.180 |
Why?
| | Drug Therapy, Combination | 5 | 2015 | 395 | 0.180 |
Why?
| | Vagina | 2 | 2018 | 46 | 0.170 |
Why?
| | Papillomavirus Vaccines | 2 | 2013 | 70 | 0.170 |
Why?
| | Etoposide | 5 | 2021 | 74 | 0.170 |
Why?
| | Spleen | 1 | 2021 | 172 | 0.170 |
Why?
| | Anti-HIV Agents | 3 | 2020 | 46 | 0.170 |
Why?
| | Enzyme Inhibitors | 2 | 2016 | 372 | 0.170 |
Why?
| | Cross-Over Studies | 1 | 2021 | 238 | 0.170 |
Why?
| | Genes, myc | 1 | 2020 | 39 | 0.170 |
Why?
| | Gene Frequency | 2 | 2017 | 98 | 0.170 |
Why?
| | Overweight | 1 | 2022 | 224 | 0.170 |
Why?
| | Transplantation, Autologous | 3 | 2018 | 488 | 0.170 |
Why?
| | Aged, 80 and over | 5 | 2013 | 3392 | 0.160 |
Why?
| | Dihydroxyphenylalanine | 1 | 2019 | 5 | 0.160 |
Why?
| | Nervous System Diseases | 1 | 2020 | 95 | 0.160 |
Why?
| | Dopaminergic Neurons | 1 | 2019 | 19 | 0.160 |
Why?
| | Ablation Techniques | 1 | 2019 | 21 | 0.160 |
Why?
| | Genitalia, Male | 1 | 2019 | 14 | 0.160 |
Why?
| | Infant, Newborn | 5 | 2024 | 2867 | 0.150 |
Why?
| | Sodium, Dietary | 1 | 2019 | 24 | 0.150 |
Why?
| | Altruism | 1 | 2018 | 13 | 0.150 |
Why?
| | Central Nervous System Diseases | 1 | 2019 | 27 | 0.150 |
Why?
| | Mouth | 1 | 2019 | 33 | 0.150 |
Why?
| | Asymptomatic Infections | 1 | 2018 | 5 | 0.150 |
Why?
| | Mitochondria | 2 | 2020 | 430 | 0.150 |
Why?
| | Dopamine | 1 | 2019 | 173 | 0.150 |
Why?
| | Antiviral Agents | 2 | 2013 | 178 | 0.150 |
Why?
| | Sexually Transmitted Diseases | 1 | 2018 | 36 | 0.150 |
Why?
| | Encephalitis | 1 | 2018 | 39 | 0.140 |
Why?
| | Hyperthermia, Induced | 1 | 2019 | 120 | 0.140 |
Why?
| | Chlamydia | 1 | 2017 | 8 | 0.140 |
Why?
| | Energy Metabolism | 1 | 2020 | 302 | 0.140 |
Why?
| | Mucous Membrane | 1 | 2017 | 31 | 0.140 |
Why?
| | Regeneration | 1 | 2018 | 79 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 2 | 2023 | 227 | 0.140 |
Why?
| | Pilot Projects | 3 | 2019 | 721 | 0.140 |
Why?
| | Blood Cells | 1 | 2017 | 45 | 0.140 |
Why?
| | Exosomes | 1 | 2018 | 58 | 0.140 |
Why?
| | Biopsy | 2 | 2022 | 605 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 528 | 0.140 |
Why?
| | DNA, Circular | 1 | 2017 | 18 | 0.140 |
Why?
| | Antibodies, Bacterial | 1 | 2017 | 30 | 0.140 |
Why?
| | Clostridium Infections | 1 | 2018 | 55 | 0.140 |
Why?
| | Clonal Evolution | 1 | 2017 | 58 | 0.130 |
Why?
| | Immunoglobulins | 1 | 2017 | 76 | 0.130 |
Why?
| | Immunoglobulin G | 1 | 2017 | 195 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 235 | 0.130 |
Why?
| | Anus Diseases | 1 | 2016 | 2 | 0.130 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2017 | 120 | 0.130 |
Why?
| | Mannitol | 1 | 2016 | 15 | 0.130 |
Why?
| | Lymph Node Excision | 1 | 2017 | 133 | 0.130 |
Why?
| | Telemedicine | 1 | 2022 | 494 | 0.130 |
Why?
| | Guidelines as Topic | 1 | 2016 | 111 | 0.130 |
Why?
| | Thiazoles | 1 | 2016 | 55 | 0.130 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2015 | 7 | 0.130 |
Why?
| | Diagnostic Self Evaluation | 1 | 2015 | 14 | 0.130 |
Why?
| | Blood-Brain Barrier | 1 | 2016 | 48 | 0.120 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 164 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2013 | 1378 | 0.120 |
Why?
| | Educational Status | 1 | 2016 | 226 | 0.120 |
Why?
| | Tinidazole | 2 | 2012 | 2 | 0.120 |
Why?
| | T-Lymphocytes | 1 | 2017 | 340 | 0.120 |
Why?
| | Imidazoles | 1 | 2016 | 124 | 0.120 |
Why?
| | Time Factors | 6 | 2023 | 2968 | 0.120 |
Why?
| | Burkitt Lymphoma | 1 | 2015 | 27 | 0.120 |
Why?
| | Drug Administration Schedule | 5 | 2020 | 374 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2017 | 258 | 0.120 |
Why?
| | Menarche | 1 | 2014 | 7 | 0.120 |
Why?
| | Stomatitis | 1 | 2014 | 16 | 0.110 |
Why?
| | Data Collection | 3 | 2023 | 290 | 0.110 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 2014 | 25 | 0.110 |
Why?
| | Obesity | 3 | 2022 | 1162 | 0.110 |
Why?
| | Immunophenotyping | 2 | 2017 | 117 | 0.110 |
Why?
| | Disease-Free Survival | 5 | 2016 | 460 | 0.110 |
Why?
| | Hypogonadism | 1 | 2013 | 11 | 0.110 |
Why?
| | Benzamides | 1 | 2013 | 50 | 0.110 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 332 | 0.110 |
Why?
| | Incidence | 4 | 2018 | 1062 | 0.110 |
Why?
| | Health Surveys | 1 | 2014 | 238 | 0.110 |
Why?
| | Urban Population | 1 | 2014 | 162 | 0.100 |
Why?
| | SEER Program | 1 | 2013 | 103 | 0.100 |
Why?
| | Regenerative Medicine | 2 | 2025 | 12 | 0.100 |
Why?
| | Organophosphonates | 1 | 2013 | 7 | 0.100 |
Why?
| | Testosterone | 1 | 2013 | 141 | 0.100 |
Why?
| | Perineum | 1 | 2013 | 26 | 0.100 |
Why?
| | DNA, Viral | 3 | 2020 | 137 | 0.100 |
Why?
| | Placebos | 1 | 2013 | 85 | 0.100 |
Why?
| | Cytosine | 1 | 2013 | 30 | 0.100 |
Why?
| | Adrenergic alpha-Antagonists | 2 | 2009 | 27 | 0.100 |
Why?
| | Heart Failure | 1 | 2019 | 565 | 0.100 |
Why?
| | Piperazines | 1 | 2013 | 118 | 0.100 |
Why?
| | tau Proteins | 1 | 2012 | 27 | 0.100 |
Why?
| | Prostate | 2 | 2015 | 116 | 0.100 |
Why?
| | Trichomonas Infections | 1 | 2012 | 2 | 0.100 |
Why?
| | Trichomonas vaginalis | 1 | 2012 | 3 | 0.100 |
Why?
| | HIV | 3 | 2023 | 25 | 0.100 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2012 | 62 | 0.100 |
Why?
| | Pyrimidines | 1 | 2013 | 199 | 0.100 |
Why?
| | Sleep | 2 | 2024 | 187 | 0.100 |
Why?
| | Vulvar Neoplasms | 1 | 2013 | 60 | 0.100 |
Why?
| | Androgen Antagonists | 1 | 2011 | 11 | 0.090 |
Why?
| | Urination Disorders | 1 | 2011 | 23 | 0.090 |
Why?
| | Sirolimus | 1 | 2012 | 65 | 0.090 |
Why?
| | Medicare | 1 | 2013 | 274 | 0.090 |
Why?
| | Comorbidity | 1 | 2013 | 625 | 0.090 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2012 | 80 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2017 | 132 | 0.090 |
Why?
| | Kenya | 2 | 2022 | 12 | 0.090 |
Why?
| | Quinazolinones | 1 | 2011 | 6 | 0.090 |
Why?
| | Human papillomavirus 16 | 2 | 2013 | 44 | 0.090 |
Why?
| | Arkansas | 1 | 2016 | 2028 | 0.090 |
Why?
| | Social Class | 1 | 2011 | 94 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2013 | 488 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2012 | 591 | 0.080 |
Why?
| | Chronic Disease | 1 | 2012 | 586 | 0.080 |
Why?
| | Piperidines | 1 | 2011 | 97 | 0.080 |
Why?
| | Prognosis | 5 | 2017 | 2099 | 0.080 |
Why?
| | Plant Bark | 1 | 2009 | 4 | 0.080 |
Why?
| | Valproic Acid | 1 | 2009 | 35 | 0.080 |
Why?
| | Multiple Myeloma | 2 | 2014 | 3049 | 0.080 |
Why?
| | Ki-67 Antigen | 1 | 2009 | 58 | 0.080 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 610 | 0.080 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 294 | 0.080 |
Why?
| | Logistic Models | 1 | 2012 | 925 | 0.080 |
Why?
| | India | 2 | 2021 | 68 | 0.080 |
Why?
| | Tetracyclines | 2 | 2006 | 9 | 0.080 |
Why?
| | Fruit | 1 | 2009 | 128 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2012 | 649 | 0.070 |
Why?
| | Antiretroviral Therapy, Highly Active | 3 | 2015 | 32 | 0.070 |
Why?
| | Survival Analysis | 3 | 2017 | 673 | 0.070 |
Why?
| | Adaptive Immunity | 2 | 2017 | 34 | 0.070 |
Why?
| | Glioblastoma | 1 | 2009 | 97 | 0.070 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 50 | 0.070 |
Why?
| | Sexual Partners | 2 | 2018 | 39 | 0.070 |
Why?
| | Stress, Psychological | 1 | 2009 | 273 | 0.070 |
Why?
| | Disease Progression | 4 | 2013 | 871 | 0.070 |
Why?
| | Regression Analysis | 2 | 2018 | 401 | 0.070 |
Why?
| | Chaperonins | 1 | 2006 | 3 | 0.060 |
Why?
| | Chaperonin 60 | 1 | 2006 | 5 | 0.060 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2006 | 13 | 0.060 |
Why?
| | Lymphocyte Count | 1 | 2006 | 20 | 0.060 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2006 | 32 | 0.060 |
Why?
| | Sexual Behavior | 2 | 2018 | 128 | 0.060 |
Why?
| | Viral Vaccines | 1 | 2006 | 16 | 0.060 |
Why?
| | Immunohistochemistry | 3 | 2017 | 979 | 0.060 |
Why?
| | HIV Protease Inhibitors | 1 | 2006 | 3 | 0.060 |
Why?
| | Interferon-alpha | 1 | 2006 | 53 | 0.060 |
Why?
| | Nephrosis, Lipoid | 1 | 2005 | 5 | 0.060 |
Why?
| | Arterioles | 1 | 2005 | 33 | 0.060 |
Why?
| | Infant | 2 | 2024 | 3733 | 0.060 |
Why?
| | Body Mass Index | 2 | 2022 | 689 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2009 | 291 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 1 | 2006 | 177 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2023 | 1026 | 0.060 |
Why?
| | Circadian Clocks | 1 | 2025 | 3 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 3 | 2017 | 87 | 0.060 |
Why?
| | Administration, Oral | 4 | 2013 | 451 | 0.060 |
Why?
| | Administration, Intranasal | 1 | 2024 | 31 | 0.060 |
Why?
| | Anti-Retroviral Agents | 2 | 2019 | 19 | 0.060 |
Why?
| | Phenotype | 2 | 2017 | 789 | 0.060 |
Why?
| | Neutropenia | 2 | 2020 | 115 | 0.060 |
Why?
| | Genotype | 2 | 2017 | 566 | 0.060 |
Why?
| | Confidence Intervals | 2 | 2015 | 158 | 0.060 |
Why?
| | Dust | 1 | 2024 | 23 | 0.050 |
Why?
| | Carbon | 1 | 2024 | 55 | 0.050 |
Why?
| | Particulate Matter | 1 | 2024 | 63 | 0.050 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2023 | 78 | 0.050 |
Why?
| | Femur Neck | 1 | 2003 | 7 | 0.050 |
Why?
| | Africa South of the Sahara | 1 | 2022 | 6 | 0.050 |
Why?
| | Hip | 1 | 2003 | 23 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 2006 | 361 | 0.050 |
Why?
| | Oligomycins | 1 | 2022 | 8 | 0.050 |
Why?
| | Rotenone | 1 | 2022 | 15 | 0.050 |
Why?
| | Galactose | 1 | 2022 | 29 | 0.050 |
Why?
| | Narcotics | 1 | 2023 | 108 | 0.050 |
Why?
| | Quality Control | 1 | 2003 | 96 | 0.050 |
Why?
| | Sample Size | 1 | 2022 | 44 | 0.050 |
Why?
| | Eating | 1 | 2023 | 159 | 0.050 |
Why?
| | Breast Feeding | 1 | 2024 | 197 | 0.050 |
Why?
| | Vitamins | 1 | 2022 | 64 | 0.050 |
Why?
| | Femur | 1 | 2003 | 135 | 0.050 |
Why?
| | Spine | 1 | 2003 | 89 | 0.050 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2002 | 10 | 0.050 |
Why?
| | Glycolysis | 1 | 2022 | 73 | 0.050 |
Why?
| | Tetracycline | 1 | 2002 | 20 | 0.050 |
Why?
| | Vitamin D | 1 | 2022 | 90 | 0.050 |
Why?
| | Radiotherapy Dosage | 1 | 2022 | 255 | 0.050 |
Why?
| | Sodium | 1 | 2022 | 95 | 0.050 |
Why?
| | Tretinoin | 1 | 2002 | 54 | 0.050 |
Why?
| | Leg | 1 | 2022 | 120 | 0.050 |
Why?
| | Fibroblast Growth Factor 2 | 2 | 2017 | 34 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2005 | 481 | 0.040 |
Why?
| | Museums | 1 | 2021 | 2 | 0.040 |
Why?
| | Alprostadil | 1 | 2021 | 10 | 0.040 |
Why?
| | Ischemia | 1 | 2022 | 150 | 0.040 |
Why?
| | Progesterone | 1 | 2020 | 58 | 0.040 |
Why?
| | Oxygen | 1 | 2023 | 336 | 0.040 |
Why?
| | Length of Stay | 1 | 2024 | 663 | 0.040 |
Why?
| | Kidney | 1 | 2005 | 707 | 0.040 |
Why?
| | Zimbabwe | 1 | 2020 | 3 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2020 | 66 | 0.040 |
Why?
| | Malawi | 1 | 2020 | 14 | 0.040 |
Why?
| | Wharton Jelly | 1 | 2020 | 2 | 0.040 |
Why?
| | Uganda | 1 | 2020 | 38 | 0.040 |
Why?
| | Software | 1 | 2003 | 280 | 0.040 |
Why?
| | Spinal Cord Injuries | 1 | 2020 | 55 | 0.040 |
Why?
| | Cell Shape | 1 | 2020 | 21 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2020 | 43 | 0.040 |
Why?
| | Body Composition | 1 | 2003 | 338 | 0.040 |
Why?
| | Neisseria gonorrhoeae | 1 | 2020 | 4 | 0.040 |
Why?
| | Glucose | 1 | 2022 | 355 | 0.040 |
Why?
| | Herpesviridae Infections | 1 | 2020 | 57 | 0.040 |
Why?
| | Ceftriaxone | 1 | 2020 | 24 | 0.040 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2020 | 58 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2021 | 184 | 0.040 |
Why?
| | Thrombocytopenia | 1 | 2020 | 89 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2020 | 82 | 0.040 |
Why?
| | Proctoscopy | 1 | 2019 | 2 | 0.040 |
Why?
| | Remission Induction | 2 | 2012 | 218 | 0.040 |
Why?
| | Interleukin-6 | 2 | 2016 | 278 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 483 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2020 | 284 | 0.040 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2019 | 52 | 0.040 |
Why?
| | Forelimb | 1 | 2018 | 4 | 0.040 |
Why?
| | Cell Survival | 1 | 2020 | 612 | 0.040 |
Why?
| | Green Fluorescent Proteins | 1 | 2018 | 93 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2013 | 192 | 0.040 |
Why?
| | Rats, Inbred F344 | 1 | 2018 | 197 | 0.040 |
Why?
| | Receptors, Chemokine | 1 | 2017 | 12 | 0.040 |
Why?
| | Models, Animal | 1 | 2019 | 234 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2018 | 233 | 0.040 |
Why?
| | Coinfection | 1 | 2018 | 47 | 0.040 |
Why?
| | Postural Balance | 1 | 2018 | 58 | 0.040 |
Why?
| | Neurodegenerative Diseases | 1 | 2019 | 80 | 0.040 |
Why?
| | Pandemics | 1 | 2022 | 585 | 0.040 |
Why?
| | Bone Marrow | 1 | 2019 | 364 | 0.040 |
Why?
| | Neurogenesis | 1 | 2017 | 27 | 0.030 |
Why?
| | Cell Separation | 1 | 2017 | 83 | 0.030 |
Why?
| | Muscle Strength | 1 | 2018 | 130 | 0.030 |
Why?
| | Cytological Techniques | 1 | 2017 | 13 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2017 | 69 | 0.030 |
Why?
| | Angiopoietin-2 | 1 | 2017 | 15 | 0.030 |
Why?
| | Angiopoietin-1 | 1 | 2017 | 16 | 0.030 |
Why?
| | Receptor, TIE-2 | 1 | 2017 | 16 | 0.030 |
Why?
| | Axilla | 1 | 2017 | 92 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2017 | 47 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2017 | 97 | 0.030 |
Why?
| | Fluorouracil | 1 | 2016 | 59 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2017 | 75 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2017 | 183 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 558 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2017 | 244 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2017 | 180 | 0.030 |
Why?
| | Mastectomy | 1 | 2017 | 143 | 0.030 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2016 | 9 | 0.030 |
Why?
| | Directly Observed Therapy | 1 | 2015 | 7 | 0.030 |
Why?
| | Urine | 1 | 2015 | 25 | 0.030 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2015 | 17 | 0.030 |
Why?
| | Vaginal Smears | 1 | 2015 | 28 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 2017 | 153 | 0.030 |
Why?
| | RNA, Viral | 2 | 2009 | 127 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2017 | 125 | 0.030 |
Why?
| | Treatment Failure | 1 | 2015 | 122 | 0.030 |
Why?
| | Prisons | 1 | 2015 | 39 | 0.030 |
Why?
| | Ifosfamide | 1 | 2015 | 9 | 0.030 |
Why?
| | Cytarabine | 1 | 2015 | 42 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2017 | 478 | 0.030 |
Why?
| | Methotrexate | 1 | 2015 | 77 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2022 | 1546 | 0.030 |
Why?
| | Induction Chemotherapy | 1 | 2014 | 64 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 2 | 2006 | 56 | 0.030 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2013 | 19 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2013 | 33 | 0.030 |
Why?
| | Depression | 1 | 2019 | 600 | 0.030 |
Why?
| | Melphalan | 1 | 2014 | 181 | 0.030 |
Why?
| | Cohort Studies | 1 | 2018 | 1542 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2013 | 87 | 0.030 |
Why?
| | Cancer Care Facilities | 1 | 2013 | 19 | 0.030 |
Why?
| | Time | 1 | 2013 | 28 | 0.030 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 55 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2017 | 990 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 220 | 0.030 |
Why?
| | Specialization | 1 | 2013 | 49 | 0.030 |
Why?
| | Demography | 1 | 2013 | 90 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 133 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 62 | 0.020 |
Why?
| | Antitrichomonal Agents | 1 | 2012 | 1 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 639 | 0.020 |
Why?
| | Reference Values | 1 | 2013 | 313 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 1327 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 90 | 0.020 |
Why?
| | Antigens, Viral | 1 | 2012 | 43 | 0.020 |
Why?
| | Medical Oncology | 1 | 2013 | 104 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 61 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2011 | 116 | 0.020 |
Why?
| | Organ Size | 1 | 2011 | 228 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 334 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 727 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2010 | 109 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2022 | 6607 | 0.020 |
Why?
| | Survival Rate | 1 | 2012 | 945 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2009 | 323 | 0.020 |
Why?
| | Busulfan | 1 | 2008 | 17 | 0.020 |
Why?
| | Psychometrics | 1 | 2009 | 230 | 0.020 |
Why?
| | Mutation | 1 | 2013 | 1347 | 0.020 |
Why?
| | Mice | 1 | 2017 | 5949 | 0.020 |
Why?
| | Ultrasonography | 1 | 2008 | 430 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2006 | 39 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2006 | 51 | 0.020 |
Why?
| | Hypertension, Renal | 1 | 2005 | 21 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2009 | 1023 | 0.020 |
Why?
| | Fatigue | 1 | 2006 | 125 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2006 | 483 | 0.010 |
Why?
| | Receptors, Interleukin-6 | 1 | 2002 | 23 | 0.010 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 9 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 14 | 0.010 |
Why?
| | Lymphokines | 1 | 2002 | 20 | 0.010 |
Why?
| | Drug Tolerance | 1 | 2002 | 60 | 0.010 |
Why?
| | Safety | 1 | 2002 | 79 | 0.010 |
Why?
| | Child, Preschool | 1 | 2005 | 4076 | 0.010 |
Why?
|
|
Lee's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|